Anti-angiogenic agent ramucirumab: meaningful or marginal? - Wikidata - wikimedia - TriplyDB

Anti-angiogenic agent ramucirumab: meaningful or marginal?

Anti-angiogenic agent ramucirumab: meaningful or marginal?

http://www.wikidata.org/entity/Q38194159

about

Clinical experience with ramucirumab : outcomes in breast cancer.The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.Isoprenaline/β2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis.

P2860

Q38228982-E0D14F30-80AB-4C9F-BFDD-48A4EFE94EA8 Q38550459-73FE7A3C-AB2F-4AC9-AC60-FE9796946639 Q38825283-8C5BE4CE-0E11-42E5-B878-4F3F83D7EBF9 Q38852051-3D9F3A53-137D-4E46-8CC5-E25CC9D22294 Q39453613-08180D3C-45EE-4E5F-BFDB-65AAF268FA88 Q46209871-94A00E80-77ED-48A0-B704-913D548E69F2 Q47158664-1AD2E157-6073-45A8-9F53-45ECE06242EB

P2860

Anti-angiogenic agent ramucirumab: meaningful or marginal?

http://www.wikidata.org/entity/Q38194159

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Anti-angiogenic agent ramucirumab: meaningful or marginal?

@en

type

label

Anti-angiogenic agent ramucirumab: meaningful or marginal?

@en

prefLabel

Anti-angiogenic agent ramucirumab: meaningful or marginal?

@en

P1433

Q38194159-D31453F2-7295-4605-BF70-8D6AC427CEEC

P1476

Q38194159-E0FD5D6C-AE2D-4E01-960D-306D0DF7D0F9

P2093

Q38194159-0A6E41D5-026A-4F9B-84D0-8F2BF96B54A5

Q38194159-1611BD30-8DB8-42BE-8329-F2F10C56588B

Q38194159-6665924C-CB3F-46B9-AF51-CF1E41323548

Q38194159-6B25A21D-93E1-454E-9587-B9DBDDB9F039

Q38194159-7260EFD3-87BB-49EC-89D5-170122C7827A

Q38194159-AB18D156-0B4A-4FB4-A46C-5F79A5B1D5D3

Q38194159-B04306BF-AF33-4FA3-AD9D-271ED85B40C2

Q38194159-E2C192A5-D7C5-4413-B921-B4D9E889A604

P2860

Q38194159-014BAFB3-A3F8-496A-819A-AE5FD3181E00

Q38194159-0516F783-11F8-4586-B1C7-44BB53A9133C

Q38194159-06BBD015-1527-45E0-B17B-FBC33274E729

Q38194159-072AE81D-0826-4C21-B7BE-5F5792F2F087

Q38194159-0A41B500-4E6B-4B31-970E-403D7329B358

Q38194159-1B4BEFC7-7CE7-47D9-B395-F8BA58528038

Q38194159-2B57EA72-9D79-4928-9BCE-B82B05680753

Q38194159-32679E61-7AE1-4E78-B822-28A3D3E40C74

Q38194159-329928BA-AEAB-439D-A9E0-255586426946

Q38194159-35CD9D38-7738-4A43-97EE-2F4B676676D2

P304

Q38194159-255A01D1-0AD0-4490-8A25-A359B3D31905

P31

Q38194159-3EA2D9E8-9275-475A-AEF4-B37263FB30DF

P356

Q38194159-80B2D3FE-37F9-4296-A4D6-216E16A748FB

P433

Q38194159-2C04A7E3-534B-426C-8730-4423BF62F699

P478

Q38194159-9BBA44A2-5659-4CFF-87EF-87127AA62082

P50

Q38194159-0EDD0A7B-4892-455C-AB8E-F9EAF5E5CEA6

P577

Q38194159-BC71A946-CB0B-4639-9804-F7CDA4CAFA81

P698

Q38194159-E14EEF8D-9508-4A67-8D23-9A8B1BCA52D8

P356

14737140.2014.896207

P1433

Expert Review of Anticancer Therapy

P1476

Anti-angiogenic agent ramucirumab: meaningful or marginal?

@en

P2093

Elena Elimova

http://www.w3.org/2001/XMLSchema#string

Hironori Shiozaki

http://www.w3.org/2001/XMLSchema#string

Jaffer A Ajani

http://www.w3.org/2001/XMLSchema#string

Jeannelyn S Estrella

http://www.w3.org/2001/XMLSchema#string

Mariela A Blum

http://www.w3.org/2001/XMLSchema#string

Qiongrong Chen

http://www.w3.org/2001/XMLSchema#string

Roopma Wadhwa

http://www.w3.org/2001/XMLSchema#string

Shumei Song

http://www.w3.org/2001/XMLSchema#string

P2860

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

Modes of resistance to anti-angiogenic therapy

The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after fir

Combining antiangiogenics to overcome resistance: rationale and clinical experience

Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies

The structural basis for the function of two anti-VEGF receptor 2 antibodies

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Tumor angiogenesis: therapeutic implications

Sorafenib in advanced hepatocellular carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

P304

367-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2014.896207

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24605771

http://www.w3.org/2001/XMLSchema#string